Items Tagged ‘Imfinzi’

April 23, 2018

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer

By

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than […]

View full entry

Tags: atezolizumab, Checkpoint inhibitors Keytruda, durvalumab, Imfinzi, kidney cancer, News, nivolumab, opdivo, pembrolizumab, Renal Cancer, renal cell cancer, Tecentriq


October 17, 2017

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

By

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi […]

View full entry

Tags: checkpoint inhibitor, durvalumab, Imfinzi, immunotherapy, keytruda, locally advanced NSCLC, Lung Cancer, News, nivolumab, opdivo, pembrolizumab, Precision Cancer Medicine